Ling Zhang1, Jun Gao, Zhaoshen Li, Yanfang Gong. 1. Department of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
Abstract
BACKGROUND: Gene silencing via promoter hypermethylation plays a crucial role in the pathogenesis of cancers. Neuronal pentraxin II (NPTX2) has been observed to be hypermethylated in pancreatic cancers. Methylation of NPTX2 might provide a novel diagnostic marker for pancreatic cancers. AIM: The objective of this study is to investigate the abnormal patterns of DNA methylation of NPTX2 in pancreatic cancers, and its role in the transcriptional silencing of NPTX2. METHODS: NPTX2 expression was detected by reverse-transcription polymerase chain reaction (RT-PCR), and the methylation status of NPTX2 was assessed by methylation-specific polymerase chain reaction (MSP). Immunohistochemistry was used to examine the NPTX2 protein expression. The pancreatic cancer cell lines were treated with the DNA methyltransferase inhibitor, histone deacetylase inhibitors, either alone or in combination. RESULTS: The MSP analysis revealed that the promoter region of NPTX2 gene was largely unmethylated in normal pancreatic tissues, while NPTX2 was frequently hypermethylated in pancreatic cancer cells and in primary pancreatic carcinomas. Quantitative RT-PCR revealed that the mean mRNA expression level of NPTX2 in the pancreatic cancer tissues was significantly lower than that in the paired adjacent normal tissues (0.96 ± 0.91 vs. 2.78 ± 1.42, P < 0.001). Consistent with RT-PCR detection, treatment with 5Aza-dC resulted in different degrees of induction of NPTX2 protein in the various cancer cell lines. CONCLUSION: We demonstrate that the NPTX2 protein is down-regulated in human primary pancreatic cancers and in pancreatic cancer cell lines. This study provides the first evidence that the down-regulation of NPTX2 tightly correlates with its promoter hypermethylation.
BACKGROUND: Gene silencing via promoter hypermethylation plays a crucial role in the pathogenesis of cancers. Neuronal pentraxin II (NPTX2) has been observed to be hypermethylated in pancreatic cancers. Methylation of NPTX2 might provide a novel diagnostic marker for pancreatic cancers. AIM: The objective of this study is to investigate the abnormal patterns of DNA methylation of NPTX2 in pancreatic cancers, and its role in the transcriptional silencing of NPTX2. METHODS:NPTX2 expression was detected by reverse-transcription polymerase chain reaction (RT-PCR), and the methylation status of NPTX2 was assessed by methylation-specific polymerase chain reaction (MSP). Immunohistochemistry was used to examine the NPTX2 protein expression. The pancreatic cancer cell lines were treated with the DNA methyltransferase inhibitor, histone deacetylase inhibitors, either alone or in combination. RESULTS: The MSP analysis revealed that the promoter region of NPTX2 gene was largely unmethylated in normal pancreatic tissues, while NPTX2 was frequently hypermethylated in pancreatic cancer cells and in primary pancreatic carcinomas. Quantitative RT-PCR revealed that the mean mRNA expression level of NPTX2 in the pancreatic cancer tissues was significantly lower than that in the paired adjacent normal tissues (0.96 ± 0.91 vs. 2.78 ± 1.42, P < 0.001). Consistent with RT-PCR detection, treatment with 5Aza-dC resulted in different degrees of induction of NPTX2 protein in the various cancer cell lines. CONCLUSION: We demonstrate that the NPTX2 protein is down-regulated in human primary pancreatic cancers and in pancreatic cancer cell lines. This study provides the first evidence that the down-regulation of NPTX2 tightly correlates with its promoter hypermethylation.
Authors: Hiroyuki Matsubayashi; Marcia Canto; Norihiro Sato; Alison Klein; Tadayoshi Abe; Keishi Yamashita; Charles J Yeo; Anthony Kalloo; Ralph Hruban; Michael Goggins Journal: Cancer Res Date: 2006-01-15 Impact factor: 12.701
Authors: Mei-Fang Xiao; Desheng Xu; Michael T Craig; Kenneth A Pelkey; Chun-Che Chien; Yang Shi; Juhong Zhang; Susan Resnick; Olga Pletnikova; David Salmon; James Brewer; Steven Edland; Jerzy Wegiel; Benjamin Tycko; Alena Savonenko; Roger H Reeves; Juan C Troncoso; Chris J McBain; Douglas Galasko; Paul F Worley Journal: Elife Date: 2017-03-23 Impact factor: 8.140
Authors: Alexandra C Nica; Halit Ongen; Jean-Claude Irminger; Domenico Bosco; Thierry Berney; Stylianos E Antonarakis; Philippe A Halban; Emmanouil T Dermitzakis Journal: Genome Res Date: 2013-05-28 Impact factor: 9.043
Authors: Sarah Schrödter; Martin Braun; Isabella Syring; Niklas Klümper; Mario Deng; Doris Schmidt; Sven Perner; Stefan C Müller; Jörg Ellinger Journal: Mol Cancer Date: 2016-02-02 Impact factor: 27.401